Prevalence of Human Papillomavirus Types 16/18 and Effect of Vaccination among Japanese Female General Citizens in the Vaccine Crisis Era

Author:

Kitamura Tadaichi,Suzuki MotofumiORCID,Shigehara KazuyoshiORCID,Fukuda Kazuko,Matsuyama Taeko,Kume Haruki

Abstract

The Japanese government withdrew its recommendation for human papillomavirus (HPV) vaccination in June 2013 and resumed it in April 2022. This period is known as the vaccine crisis in Japan. This study aimed to elucidate the prevalence and genotype distribution of HPV among Japanese female citizens, and the effect of vaccination against HPV-16/18 in the era of the vaccine crisis. We recruited Japanese female citizens and asked them to provide self-collected samples from the vaginal wall using cotton swabs for HPV genotyping. Furthermore, we collected the participants’ characteristics, including lifestyle and experience of vaccination against HPV, to determine the significant association with HPV infection. HPV-16/18 positivity was found in 5.6% (115/2044) of participants. The highest vaccination rate was observed in the age group of 20–24 years (60.6%), whereas the lowest HPV-16/18 positivity was observed in the age group of 45–49 years (2.8%), followed by the age group of 20–24 years (4.0%). Experience with HPV vaccination significantly reduced the risk of HPV-16/18 infection (adjusted odds ratio, 0.047; 95% confidence interval, 0.011–0.196). Vaccinated women were much less likely to be infected by HPV-16/18, regardless of the HPV vaccine type or the vaccination dose.

Funder

The Japanese Foundation for Sexual Health Medicine, Tokyo, Japan

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Reference31 articles.

1. (2022, October 10). GLOBOCAN 2020. Available online: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.

2. (2022, October 10). CANCER STATISTICS IN JAPAN. Available online: https://ganjoho.jp/reg_stat/statistics/stat/cancer/17_cervix_uteri.html.

3. Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011;Katanoda;Jpn. J. Clin. Oncol.,2017

4. (2022, December 31). World Health Organization, Immunization, Vaccines and Biologicals. Available online: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-(HPV).

5. (2022, December 31). World Health Organization, Cervical Cancer. Available online: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3